# A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

> **NCT05009069** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 58 (actual)

## Conditions studied

- Rectal Neoplasms
- Rectal Cancer

## Interventions

- **RADIATION:** Radiotherapy
- **DRUG:** Capecitabine
- **DRUG:** Fluorouracil
- **DRUG:** Atezolizumab
- **DRUG:** Tiragolumab

## Key facts

- **NCT ID:** NCT05009069
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-18
- **Primary completion:** 2023-11-21
- **Final completion:** 2026-11-10
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05009069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05009069, "A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05009069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*